BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27592476)

  • 1. Impact of the radiotherapy combined with cisplatin plus paclitaxel chemotherapy on the immunologic functions in the patients with esophageal cancer.
    Liu R; Zhang J; He C; Jiang Q; Liu J; Fan R
    Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1387-90. PubMed ID: 27592476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
    Jiang YY; Wu SX; Zhang P; Xie CY; Wang J; Sun CC
    Zhonghua Yi Xue Za Zhi; 2008 Aug; 88(31):2171-4. PubMed ID: 19080664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma.
    Hsu FM; Lee JM; Huang PM; Lin CC; Hsu CH; Tsai YC; Lee YC; Chia-Hsien Cheng J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e593-9. PubMed ID: 21658851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancer.
    Ruppert BN; Watkins JM; Shirai K; Wahlquist AE; Garrett-Mayer E; Aguero EG; Sherman CA; Reed CE; Sharma AK
    Am J Clin Oncol; 2010 Aug; 33(4):346-52. PubMed ID: 19841574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report.
    Henry LR; Goldberg M; Scott W; Konski A; Meropol NJ; Freedman G; Weiner LM; Watts P; Beard M; McLaughlin S; Cheng JD
    Ann Surg Oncol; 2006 Feb; 13(2):214-20. PubMed ID: 16418887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
    Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
    Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma].
    Zeng SY; Li L; Zhong ML; Jiang W; Wu YY; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):517-9. PubMed ID: 22093629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
    Kelsey CR; Chino JP; Willett CG; Clough RW; Hurwitz HI; Morse MA; Bendell JC; D'Amico TA; Czito BG
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):770-6. PubMed ID: 17889266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up.
    Zemanova M; Petruzelka L; Pazdro A; Kralova D; Smejkal M; Pazdrova G; Honova H
    Dis Esophagus; 2010 Feb; 23(2):160-7. PubMed ID: 19515190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radiation therapy with or without concurrent chemotherapy for node-positive thoracic esophageal squamous cell carcinoma.
    Chen J; Pan J; Liu J; Li J; Zhu K; Zheng X; Chen M; Chen M; Liao Z
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):671-7. PubMed ID: 23773390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
    Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
    Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    Kim DW; Blanke CD; Wu H; Shyr Y; Berlin J; Beauchamp RD; Chakravarthy B
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):397-404. PubMed ID: 17097833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
    Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.
    Boggs DH; Tarabolous C; Morris CG; Hanna A; Burrows W; Horiba N; Suntharalingam M
    Dis Esophagus; 2015 Oct; 28(7):619-25. PubMed ID: 24863682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.